Nuclear Medicine and Molecular Imaging

The Korean Society of Nuclear Medicine (대한핵의학회)
권호 표지

Comparison of $Na^+/I^-$ Symporter Expression Rate in Malignant and Benign Thyroid Diseases: Immunohistochemical Study

악성 및 양성 갑상선 질환의 조직에서 면역조직학적 검사법에 의한 $Na^+/I^-$ symporter의 발현율 비교

  • Kang, Do-Young (Department of Nuclear Medicine, Dong-A University College of Medicine) ;
  • Jeong, Young-Jin (Department of Nuclear Medicine, Dong-A University College of Medicine) ;
  • Lee, Kyung-Eun (Medical Research Center for Cancer Molecular Therapy, Dong-A University College of Medicine) ;
  • Park, Heon-Soo (Department of Otolaryngology-Head and Neck Surgery, Dong-A University College of Medicine) ;
  • Yoo, Young-Hyun (Medical Science Research Center, Dong-A University College of Medicine) ;
  • Roh, Mee-Sook (Medical Research Center for Cancer Molecular Therapy, Dong-A University College of Medicine)
  • 강도영 (동아대학교 의과대학 핵의학교실) ;
  • 정영진 (동아대학교 의과대학 핵의학교실) ;
  • 이경은 (동아대학교 의과대학 암분자치료연구센터) ;
  • 박헌수 (동아대학교 의과대학 이비인후과학교실) ;
  • 유영현 (동아대학교 의과대학 의과학연구소) ;
  • 노미숙 (동아대학교 의과대학 암분자치료연구센터)
  • Published : 2006.02.28
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose: Previous studies have not showed consistent results for the level of expression of sodium/iodide symporter (NIS) in thyroid diseases, especially malignant tumor. We undertook this study to evaluate the distribution of NIS expression in malignant thyroid diseases and compare with that in benign thyroid disease. Materials and Methods: Total patients were 119 cases (Men 15, $48{\pm}13$ yrs). Total number of samples were 205 pieces. In malignant thyroid disease, there were 153 samples: 90 in papillary carcinoma, 4 in follicular carcinoma, 2 in medullary carcinoma and 57 in metastatic lymph node. In benign thyroid disease, there were 52 samples: 36 in goiter/cyst, 11 in thyroiditis and 5 in follicular adenoma. Using immunohistochemical methods, we probed 205 samples with monoclonal anti-NIS Ab. Grading of staining was stored as 0 (negative or absent), 1 (weakly positive), 2 (moderately positive) or 3 (strongly positive). Expression rate (ER) of NIS positivity in individual disease entity was expressed as percentage of total number divided by number in 2 plus 3 grade. Results: ERs of malignant thyroid diseases were 63% in papillary carcinoma, 81% in metastatic lymph node, 71% in follicular carcinoma and 100% in medullary carcinoma. ERs of benign thyroid disease were 53% in goiter/cyst, 64% in thyroiditis and 40% in follicular adenoma. ER of malignant thyroid diseases was higher than benign thyroid diseases (71% vs 54%). Grading of NIS expression in papillary carcinoma or goiter/cyst was heterogeneously distributed in considerable cases. Normal tissue also showed heterogeneous distribution of NIS expression, which was not correlated with that of primary lesion. Conclusion: In papillary thyroid carcinoma, distribution of NIS expression was heterogeneous and increased, and not different compared with that of benign thyroid disease.

목적 : 기존의 연구는 갑상선 악성 종양에서 NIS 단백질 발현에 대해 충분한 증례에서 일관성 있는 결과를 보이지 못하고 있다. 이에 본 연구에서는 원발성 갑상선 악성 종양의 조직에서 NIS 발현율의 분포를 알아보고, 이를 양성 갑상선 질환에서의 NIS 발현율의 분포와 비교하였다. 대상 및 방법 : 악성 갑상선 종양이나 양성 갑상선 질환으로 수술을 시행한 환자들을 대상으로 후향적 분석을 하였다. 환자들은 총 119명(남자 15명)이며. 나이는 $48{\pm}3$세(범위 20-75세) 였다. 이들에게서 얻은 조직 표본은 총 205개 였다. 이 표본들은 악성 질환(총 153개)으로 유두상 종양이 90개, 여포상 종양이 4개, 수질상 종양이 2개, 전이성 임파절이 57개 였으며, 양성 질환(총 52개)으로 갑상선 종대가 36개, 갑상선염이 11개, 여포선종이 5개였다. 단클론 항체인 mouse anti-NIS Ab를 사용하였다. 염색된 조직을 현미경으로 관찰하여 양성 등급은 염색 강도에 따라 약하게 염색되면 등급 1, 중등도로 염색되면 등급 2, 강하게 염색되면 등급 3으로 나누었으며, 음성인 경우는 등급 0으로 표시하였다. 개개의 질환에 있어서 NIS의 발현율은 전체의 개수에 대하여 등급 2와 3이 차지하는 비율을 백분율로 표시하였다. 결과: 갑상선 악성 질환에서 NIS의 발현율은 유두상 종양의 원발성 종양에서 63%, 전이성 임파선에서 81%를 보였다. 여포상 종양과 수질상 종양의 NIS의 발현율은 각각 71, 100% 였다. 갑상선 양성 질환에서 NIS의 발현율은 갑상선 종대에서 53%, 갑상선염에서 64%, 여포선종에서 40%였다. NIS의 발현율은 악성 종양에서 양성 질환보다 더 높았다(71% vs 54%) 증례수가 많은 유두상 종양과 갑상선 종대의 경우에 한쪽 등급에만 치우침이 없이 모든 등급에 걸쳐 분포를 보이는 특징을 보였다. 갑상선 질환을 보이는 병변 조직의 주위에 있는 정상 조직의 염색 정도는 다양한 등급을 보여서 일관성을 보이지는 않았으며, 병변조직의 염색 정도와도 연관성을 보이지 않았다. 결론: 갑상선 유두상 종양에서 면역조직화학검사에 기초한 NIS의 발현율은 불균질성 분포를 나타내며 증가하는 양상을 보였고, 악성 질환과 양성 질환 사이에 NIS의 발현율이 큰 차이를 보이지 않았다.

Keywords

References

  1. Filetti S, Bidart JM, Arturi F, Caillou B, Russo D, Schlumberger M. Sodium/iodide symporter: a key transport system in thyroid cancer cell metabolism. Eur J Endocrinol 1999;141:443-57 https://doi.org/10.1530/eje.0.1410443
  2. Dai G, Levy O, Carrasco N. Cloning and characterization of the thyroid iodide transporter. Nature 1996;379:458-60 https://doi.org/10.1038/379458a0
  3. Smanik PA, Liu Q, Furminger TL, Ryu K-Y, Xing S, Mazzaferri EL, et al. Cloning of the human sodium iodide symporter. Biochem. Biophys Res Commun 1996;226:339-45 https://doi.org/10.1006/bbrc.1996.1358
  4. Smanik PA, Ryu Ky, Theil KS, Mazzaferri EL, Jhiang SM. Expression, exon-intron organization, and chromosome mapping of the human sodium iodide symporter. Endocrinology 1997;138: 3555-8 https://doi.org/10.1210/en.138.8.3555
  5. Spitzweg C, Joba W, Eisenmenger W, Heufelder AE. Analysis of human sodium iodide symporter gene expression in extrathyroidal tissues and cloning of its complementary deoxyribonucleic acids from salivary gland, mammary gland, and gastric mucosa. J Clin Endocrinol Metab 1998;83:1746-51 https://doi.org/10.1210/jc.83.5.1746
  6. Vayre L, Sabourin J-C, Caillou B, Ducreux M, Schlumberger M, Bidart J-M. Immunohistochemial analysis of $Na^{+}$/$I^{-}$ symporter distribution in human extra-thyroidal tissues. Eur J Endocrinol 1999;141:382-6 https://doi.org/10.1530/eje.0.1410382
  7. Carrasco N. Thyroid iodide transport: The $Na^{+}/I^{-}$ symporter (NIS). In: Braverman LE, Utiger RD, editors. The thyroid. 8th ed. Philadelphia : Lippincott Williams & Wilkins; 2000. p. 52-61
  8. Saito T, Endo T, Kawaguchi A, Ikeda M, Katoh R, Kawaoi A, et al. Increased expression of the sodium/iodide symporter in papillary thyroid carcinomas. J Clin Invest 1998;101:1296-300 https://doi.org/10.1172/JCI1259
  9. Caillou B, Troalen F, Baudin E, Talbot M, Filetti S, Schlumberger M, et al. $Na^{+}$/$I^{-}$ symporter distribution in human thyroid tissues: An immunohistochemical study. J Clin Endocrinol Metab 1998;83:4102-6 https://doi.org/10.1210/jc.83.11.4102
  10. Lee C-H, Yang A-H, Chang J-Y, Huang C-L, Chi C-W. Immunohistochemical studies of $Na^{+}$/$I^{-}$symporter in human thyroid tissues - A correlation with clinical thyroid scintigraphy. Chin Med J(Taipei) 2001;64:141-6
  11. Min J-J, Chung J-K, Lee YJ, Jeong JM, Lee DS, Jang JJ, et al. Relationship between expression of the sodium/iodide symporter and $^{131}I$ uptake in recurrent lesions of differentiated thyroid carcinoma. Eur J Nucl Med 2001;28:639-45 https://doi.org/10.1007/s002590100509
  12. Castro MR, Bergert ER, Goellner JR, Hay ID, Morris JC. Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J Clin Endocrinol Metab 2001;86: 5627-32 https://doi.org/10.1210/jc.86.11.5627
  13. Hedinger C, Williams ED, Sobin LH. Histological typing of thyroid tumors. In: World Health Organization. International histological classification of tumors. 2nd ed. Berlin : Springer- Verlag: 1988
  14. Wapnir IL, Rijn M, Nowels K, Amenta PS, Walton K, Montgomery K, et al. Immunohistochemical profile of the sodium/iodide symporter in thyroid, breast, and other carcinomas using high density tissue microarrays and conventional sections. J Clin Endocrinol Metab 2003;88:1880-8 https://doi.org/10.1210/jc.2002-021544
  15. Levy O, Ginter CS, Vieja AD, Dai G, Riedel C, Carrasco N. N-linked glycosylation of the thyroid $Na^{+}$/$I^{-}$ symporter (NIS). Thyroid 1997;7(Suppl1):S22
  16. Kogai T, Curcio F, Hyman S, Cornford EM, Brent GA, Hershman JM. Induction of follicle formation in long-term cultured normal human thyroid cells treated with thyrotropin stimulates iodide uptake but not sodium/iodide symporter messenger RNA and protein expression. J Clin Endocrinol Metab 2000;167:125-35
  17. Riedel C. Levy O, Carrasco N. Post-transcriptional regulation of the sodium/iodide symporter by thyrotropin. J Biol Chem 2001;276:21458-63 https://doi.org/10.1074/jbc.M100561200
  18. Kaminsky SM, Levy O, Salvador C, Dai G, Carrasco N. $Na^{+}/I^{-}$ symporter activity is present in membrane vesicles from thyrotropin-deprived non-$I^{-}$-transporting cultured thyroid cells. Proc Natl Acad Sci USA 1994;91:3789-93
  19. Arturi F, Russo D, Schlumberger M, Villard JA, Caillou B, Vigneri P, et al. Iodide Symporter Gene Expression in Human Thyroid Tumors. J Clin Endocrinol Metab 1998:83:2493-6 https://doi.org/10.1210/jc.83.7.2493
  20. Chung JK. Sodium iodide symporter: Its role in nuclear medicine. J Nucl Med 2002;43:1188-200
  21. Lewis MR. A 'New' reporter in the field of imaging reporter genes: Correlating gene expression and function of the sodium/iodide symporter. J Nucl Med 2006;47:1-3
  22. Vadysirisack DD, Shen DH, Jhiang SM. Correlation of Na/$I^{-}$ symporter expression and activity: Implications of Na/$I^{-}$ symporter as an imaging reporter gene. J Nucl Med 2006;47:182-90